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Abstract
Breast cancers can recur after removal of the primary tumor and treatment to eliminate remaining tumor cells. Recurrence
may occur after long periods of time during which there are no clinical symptoms. Tumor cell dormancy may explain these
prolonged periods of asymptomatic residual disease and treatment resistance. We generated a dormancy gene signature
from published experimental models and applied it to both breast cancer cell line expression data as well as four published
clinical studies of primary breast cancers. We found that estrogen receptor (ER) positive breast cell lines and primary tumors
have significantly higher dormancy signature scores (P,0.0000001) than ER- cell lines and tumors. In addition, a stratified
analysis combining all ER+ tumors in four studies indicated 2.1 times higher hazard of recurrence among patients whose
tumors had low dormancy scores (LDS) compared to those whose tumors had high dormancy scores (HDS) (p,0.000005).
The trend was shown in all four individual studies. Suppression of two dormancy genes, BHLHE41 and NR2F1, resulted in
increased in vivo growth of ER positive MCF7 cells. The patient data analysis suggests that disseminated ER positive tumor
cells carrying a dormancy signature are more likely to undergo prolonged dormancy before resuming metastatic growth.
Furthermore, genes identified with this approach might provide insight into the mechanisms of dormancy onset and
maintenance as well as dormancy models using human breast cancer cell lines.
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Introduction
The major cause of death from breast cancer is metastasis: the
growth of disseminated tumor cells (DTCs) that lodge in distant sites
prior to primary tumor surgery. Most successful adjuvant treatments
developed to attack DTCs and micrometastases are based on
targeting the increased proliferation rate of tumor cells compared to
normal cells [1]. Thus, actively proliferating tumor cells are killed or
growth-suppressed by adjuvant treatments. However, non-prolifer-
ating, dormant DTCsmay remainunscathed.Tumor celldormancy
reflects the capability of DTCs or micrometastases to remain at such
low numbers that they are undetected for long periods of time [2–5].
Modeling of dormancy suggests that this could happen through the
induction of quiescence, through balanced proliferation and death
due to an impaired angiogenic switch or through immune control
[4]. In this report, we test whether the currently available gene
expression signatures for dormancy from experimental models that
reflect quiescence and angiogenesis regulation could be used to
evaluate breast cancer outcome. We find that the dormancy
signature is indeed correlated with clinical parameters. Among ER
positive tumors, a higher dormancy score is significantly associated
with lower hazard of metastasis.
Results
Models of in vivo tumor dormancy driven by tumor cell
quiescence [6] or angiogenic failure [7] have identified gene
signatures associated with these phenotypes. We hypothesized that
these signatures would be helpful in identifying tumors whose
disseminated cells would be more prone to undergo dormancy.
Based on these expression profiles, we generated a 49-gene
signature for tumor cell dormancy (Table 1), in which we consider
genes upregulated in dormant cells as positive dormancy genes and
genes downregulated in dormant cells as negative dormancy genes.
For each gene, we scaled the expression intensities by dividing them
by their average intensity across samples. Then we defined the
dormancy score (see Materials and Methods) as the difference
between the sum of log intensities of the positive dormancy genes
and the sum of the log intensities of the negative dormancy genes.
All genes were equally weighted in their contributions to the
dormancy score. Thus, we set out to determine whether tumors or
cell lines that have a higher dormancy score showed any association
with clinico-pathological parameters.
We first applied the dormancy score to published microarray
data of 51 breast cancer cell lines grown in tissue culture [8]. We
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higher dormancy scores than ER negative ones (p,0.0001; Mann-
Whitney test). As a general trend, as the dormancy score increases,
the cell line type changes from basal type B to basal type A to
luminal (Figure 1A). A cluster of 6 positive dormancy genes
(STAT3, HIST1H2BK, CTSD, SREBF1, IGFBP5 and DDR1) is
more highly expressed in lines with higher dormancy scores.
Conversely, a larger cluster of negative dormancy genes is
upregulated in lines with lower dormancy scores. Included in this
cluster are pro-proliferative genes (NT5E, IL8, PLAT, FOSL1,
ODC1). The expression profiles of genes positively correlated with
dormancy tended to be less homogeneous compared that of the
genes inversely correlated with dormancy (Figure 1A). This might
be because these expression profiles were obtained from breast
cancer cells proliferating in culture while dormancy is mediated by
aG 0 2G1 arrest not achieved in these conditions. Thus, the
Table 1. Dormancy signature genes.
Status in
Dormant Cells Gene Symbols
Up-regulated ACVR1, ADAM10, AMOT, BHLHE41, COL1A1, COL4A5, CTSD,
DDR1, EPHA5, GATA6, HIST1H2BK, IGFBP5, MMP2, NR2F1,
P4HA1, SOX9, SREBF1, STAT3, TGFB2, THBS1, TP53, TPM1
Down-regulated APEX1, ASNS, ATF3, ATF4, BUB1, BUB1B, CDKN3, CEBPG,
CKS2, DNMT1, DTYMK, EGFR, EGR1, ESM1, FOSL1, FOXD1,
FOXM1, IGF1R, IL8, JUN, MMP1, NT5E, ODC1, PIK3CB, PLAT,
TIMP3, TK1
doi:10.1371/journal.pone.0035569.t001
Figure 1. Clustering of dormancy signature scores. A) Dormancy score analysis in breast cancer cell lines. The cell lines are ordered by
dormancy scores (low to high from left to right). The rows correspond to genes and the columns represent cell lines. Expression levels for positive
dormancy genes (upregulated genes - top section) and negative dormancy genes (downregulated genes - bottom section) were clustered by a
hierarchical clustering algorithm. The colors represent log2 fold change compared to the average from 22.5 (blue, below average) to +2.5 (red, above
average) with white as the average value. A, B, and L stand for Basal A, Basal B, and Luminal classifications, respectively. B) Correlation of cell line
dormancy scores with proliferation indices from Table 1 of [9] with ER- lines plotted as squares and ER+ lines plotted as diamonds. Straight line fits of
ER- (blue, Spearman correlation coefficient r=.027) and ER+ (red, r=20.76) cell lines are plotted. The ER status of HCC1500 is unclear (ATCC indicates
it as ER+ while it is ER- by gene expression and Western blot in [8]) and it was not used in the analysis. MDA-MB-231 (large orange square), MCF7
(large green diamond) and T47D (large yellow diamond) are identified. C) Patient tumor analysis. The four clinical studies were clustered as in A. In the
ER status bar, ER status is indicated by black (ER+), blue (ER2) or white (not determined) bars. The two genes for which probes were not present in
the van de Vijver et al. data set are represented by gray bars. D) Comparison of clustering of cell lines and patient data. Top: Positive dormancy genes
that are upregulated in high dormancy score cell lines or patients. Bottom: Negative dormancy genes that are up regulated in low dormancy score
cell lines or patients.
doi:10.1371/journal.pone.0035569.g001
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expression in vivo.
To evaluate in vivo dormancy properties of these subgroups,
GFP labeled MDA-MB-231, MCF7, and T47D cells were labeled
with Cell Trace Violet and injected into the mammary fat pads of
SCID mice. After 3 days, the retained label and proportions of
GFP positive cells were determined by FACS. Label retention was
positively correlated with dormancy signature score (Spearman
correlation coefficient +0.71, p,.01). The proportion of GFP
labeled cells in the mammary fat pad was inversely correlated with
dormancy signature score (Spearman coefficient 2.857, p,.001),
consistent with increased dormancy. We next determined if there
was any association between the dormancy score and the inherent
proliferative capacity of these cancer cell lines. To this end we
compared the dormancy score with published proliferation indices
measured in 3D growth conditions available for 22 of the cell lines
[9]. We found that there was no statistically significant correlation
between proliferation index and dormancy score for ER- cell lines
(p..9), but a significant correlation for ER+ cell lines (Spearman
correlation coefficient 20.76, p,.01, Figure 1B). Thus, the
dormancy score is indicative of a program that imposes slower
growing kinetics on ER+ tumor cells in 3D culture, suggesting that
it might be indicative of slow proliferation or quiescence in vivo.
To test if the in vivo conditions in patients reveal a similar or
better relationship between the dormancy scores and breast cancer
progression, we evaluated the dormancy signatures of clinical
breast cancer samples. We used four published microarray data
sets that included well annotated invasive breast cancers with at
least seven years of follow-up [8,10–13]. We performed an analysis
of all the samples in the four studies, stratified by study, and found
that the dormancy scores were significantly higher in ER+ tumors
compared to ER- tumors (p,0.0000001; stratified Mann-Whitney
rank sum test, Table 2). This is consistent with our analysis of the
breast cancer cell lines. Analysis of the individual studies also
showed a significantly higher dormancy score in ER+ vs. ER-
tumors in three out of four (p,0.001) while one study [10] showed
a weak trend in the same direction (Table 2). Thus, although the
genes selected for the dormancy score were identified from gene
expression patterns of cell lines grown in tissue culture, their
predictive value for an in vivo phenotype in the experimental
models [6,7] could be extended to differentiating between primary
tumors with different ER status.
Examination of the clustering of the clinical samples revealed a
difference between the positive and negative dormancy genes
(Figure 1C). The set of negative dormancy genes that was
upregulated in the tumors with low dormancy scores was similar to
the set that we observed in the cell lines; of the 22 negative
dormancy genes that were upregulated in the cell lines with low
dormancy scores, 19 were also upregulated in tumors with low
dormancy scores, and one additional gene was upregulated in the
tumors with low dormancy scores (APEX1). However, there was a
more dramatic change in the positive dormancy genes. As noted
above, in the cell lines with high dormancy scores there were fewer
positive dormancy genes that were upregulated (6), and of those 5
were also upregulated in tumors with high dormancy scores.
However, in patient tumors with high dormancy scores there were
an additional 12 positive dormancy genes that were upregulated
(Figure 1D). This indicates that in vivo the positive dormancy
genes are more synchronously expressed and this may prime these
cells upon dissemination to fully enter a G0–G1 arrest in
secondary sites.
We then tested the association between dormancy and distant
metastasis free survival. Time to metastasis was determined as a
measure of the persistence of asymptomatic and possibly dormant
disease. In all four studies, patients whose ER+ tumors had higher
dormancy scores showed significantly or moderately significantly
reduced rate of recurrence (Table 3). A stratified proportional
hazards model combining all ER+ tumors in the four studies
indicated 2.1 times higher hazard of metastasis among patients
with LDS tumors compared to those with HDS tumors
(p,0.000005). Kaplan Meier plots confirmed the correlation of
dormancy score with survival for ER+ tumors but not for ER-
tumors (Figure 2).
The data gathered in Figures 1and 2 revealed that ER+ luminal
type tumor cells carry a dormancy gene signature. We hypoth-
esized that some of these genes might contribute to dormancy of
ER+ tumor cells. We have previously shown that both BHLHE41
and NR2F1 are required for or associated with dormancy of
squamous carcinoma cells [6]. Thus, we tested in the ER+ luminal
type breast cancer cell line MCF-7 whether knocking down these
genes affected latency and subsequent tumor growth. MCF-7 is
known to show long latency periods before achieving a high rate of
Table 2. Dormancy scores of ER positive and ER negative
tumors.
Study P value* P value from stratified test
#
Van de Vijver et al ,0.00001 P,0.0000001 (Z=9.2)
Wang et al. ,0.00001
Pawitan et al. ,0.001
Loi et al. 0.82
*The statistical significance of the difference in dormancy score between ER+
and ER2 tumors was determined using the Mann-Whitney rank sum test.
#Mann-Whitney rank sum test (van Elteren’s test) stratified by studies using all
samples from 4 studies.
doi:10.1371/journal.pone.0035569.t002
Table 3. Hazard ratios of metastasis for ER+ tumors according to dormancy score.
Study P value* Hazard Ratio** 95% confidence interval P-value from stratified analysis
#
Van de Vijver et al. 0.001 2.62 (1.44, 4.77) P,0.000005
Pawitan et al. 0.014 3.31 (1.19, 9.20)
Wang et al. 0.052 1.66 (0.99, 2.77)
Loi et al. 0.050 1.94 (0.99, 3.80)
*The metastasis-free survival times of ER + tumors in high dormancy score and low dormancy score groups were compared using Cox’s proportional hazard model.
**Hazard of metastasis among patients with low dormancy score relative to those with high dormancy score.
#Cox’s PH analysis stratified by studies using all samples from four studies.
doi:10.1371/journal.pone.0035569.t003
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35569Figure 2. Metastasis-free analysis for four clinical studies. (A, B) van de Vijver et al., (C, D) Loi et al., (E,F) Wang et al., (G, H) Pawitan et al.
Kaplan Meier estimates of metastasis-free proportion among patients with high (upper third, green), medium (middle third, red), and low (bottom
third, black) dormancy scores for patients with ER+ (A,C,E,F) and ER2 (B,D,F,G) tumors.
doi:10.1371/journal.pone.0035569.g002
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required to maintain dormancy then this phase should be
shortened and/or the tumor-take enhanced.
MCF-7 cells were transfected for 24 hrs with a control
scrambled siRNA or siRNAs targeting NR2F1 or BHLHE41,
then injected into the mammary fat pads of female NSG mice
(Figure 3A–B) with a fraction of the cells used to evaluate mRNA
knock down using qPCR (Figure 3C and D). The siRNAs caused
a.75% reduction in BHLHE41 or NR2F1 mRNA normalized to
GAPDH (Figure 3C and D). Three days after injection in the fat
pad and thereafter the mice were monitored for tumor take. We
found that 12 days after tumor cell injection only 40% of the mice
injected with control siRNA-treated cells had palpable tumors,
while palpable tumors were present in 100% of the mice injected
with BHLHE41 or NR2F1 siRNA treated cells (Figure 3A–B).
Furthermore, the tumors produced by BHLHE41 and NR2F1
siRNA treated MCF-7 cells appeared to proliferate faster; the final
tumor volume at day 12 was significantly larger for tumors
produced by BHLHE41 and NR2F1 siRNA treated cells
compared to those produced by control siRNA treated cells
(Figure 3A–B). These results demonstrate that the genes identified
in the dormancy signature are functional in ER+ luminal breast
cancer cell lines in limiting tumor growth, possibly through the
induction of a dormant phenotype.
Discussion
We present a dormancy score based on gene signatures developed
by combining dormancy expression profiles from a variety of cancer
types using even-weighting of all the genes. Although neither
recurrence information nor ER status was used to select these genes
or to refine the scores, we found that luminal, ER+ breast cancers
were more likely to have a high dormancy score. Positive dormancy
genes were more synchronously upregulated in patient tumors than
incelllinesgrowninvitro,demonstratingtheimportanceofthetumor
microenvironment on dormancy properties. Furthermore, the rate
of recurrence was significantly reduced for patients whose tumors
were ER+ and had a high dormancy score. These results are
consistent with the observed clinical outcome that ER+ tumors tend
to recur later than ER- tumors [15]. Furthermore, since the analysis
utilized data from primary tumors, which in some cases came from
in patients that underwent mastectomy, the findings suggest that
DTCs coming from ER+ tumors with a high dormancy score are
more likely to enter a dormancy state.
Figure 3. RNAi suppression of dormancy upregulated genes accelerates tumor take and growth of ER+ luminal MCF-7 cells.
(A) Percent of tumor take at the indicated time points after injecting with 4 10
6 MCF7 cells treated with the indicated siRNAs in the mouse mammary
fat pad. (B) Tumor volume (mm
3) at 12 days for tumors generated by MCF7 cells treated with the indicated siRNAs and injected in the mouse
mammary fat pad. (C–D) Q-PCR analysis for the expression of BHLHE41 (C) and NR2F1 (D) mRNAs after 48 hrs of treatment with control or specific
siRNAs targeting these mRNAs.
doi:10.1371/journal.pone.0035569.g003
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proliferation indices of ER+ cell lines and dormancy score, with
increased dormancy score correlating with reduced 3D proliferation
index. However, there was no statistically significant correlation
between 3D proliferation index and dormancy score for ER- cell
lines. This parallels the patient data, in which the dormancy
signature inversely correlates with rate of recurrence for patients
with ER+ tumors but not for patients with ER- tumors. This raises
the possibility that 3D proliferation index could be used as a
surrogate in vitro assay to explore dormancy mechanisms in ER+
tumors, which would then be validated with in vivo assays. It also
suggests that dormancy in vivo could reflect a reduced proliferation
rate, as evidenced by the frequent lack of proliferation markers in
DTCs (Aguirre-Ghiso, 2007). This slow proliferation or quiescence
phenotype could explain the presence of non-productive residual
disease by limiting the disseminated tumor cell population to a
steady state level, potentially complemented by immune attack and
limited angiogenesis. Comparing the dormancy scores of luminal A
vs luminal B tumors (which have a higher proliferation index [16])
in the van de Vijver and Pawitan datasets is consistent with this
possibility: the median dormancy score is significantly lower in the
luminal B tumors compared to the luminal A tumors (van de Vijver:
p,10
24 and Pawitan: p,10
25). Intriguingly, in a meta-analysis of
allluminalBtumorsfromthetwodatasets,wefound2.6timeslower
hazard of metastasis among patients with high dormancy score
tumors compared to those with low dormancy scores (p,.04),
indicating that the dormancy score has potential value for
differentiating between patients within this subtype of tumors.
The dormancy signature also incorporates elements of p38
signaling [6], and p38-induced quiescence combined with reduced
ability to undergo an angiogenic switch might contribute to ER+
tumor cell dormancy. Several genes in the dormancy signature
derived from quiescent cells [6] are regulators of angiogenesis. For
example, THBS1 is an angiogenesis inhibitor induced by p38
[6,17,18]. It is possible that emergence from prolonged quiescence
requires the immediate recruitment of blood vessels to support
nascent tumor expansion and that might explain why anti-
angiogenic genes are embedded in the quiescence signature. Genes
such as BHLHE41 (also referred to as BHLHB3 or Sharp-1),
NR2F1 and p53 have been linked to the induction of quiescence in
an experimental system [6]. Furthermore, BHLHE41 was indepen-
dently discovered as a metastasis suppressor gene in breast cancer
[19]. This suggests that these genes might be prevalent transcription
factors required for persistent induction of dormancy to suppress
metastatic growth. This is further supported by our findings that
BHLHE41 or NR2F1 knock down strongly stimulated tumor take
and growth of MCF-7 ER+ luminal cancer cell lines during the
initial dormancy phase that precedes logarithmic tumor growth.
It is interesting to speculate that dormancy signatures might be
developed for other breast cancer subtypes such as ER- tumors,
and that the genes involved would presumably reflect subtype-
specific quiescence mechanisms. Targeted treatments that lead to
maintenance of the activity of genes that induce dormancy in a
breast cancer subtype might be useful in prolonging quiescence,
keeping the disease in a chronic state. Alternatively, inhibition of
key survival genes in subtype-specific pathways could attack
dormant tumor cells before they resume growth and progression,
thereby reducing the risk of recurrence.
Materials and Methods
Dataset sources
We downloaded expression data set of 51 breast cancer cell lines
and ER status of the cell lines from Neve et al. [8], in which
expression profiles were measured using Affymetrix HG-U133A
arrays. We downloaded expression data sets of human breast
tumors published by Pawitan et al. ([12], n=159), Loi et al ([10]
n=327), Wang et al. ([11], n=286), and van de Vijver et al. ([13]
n=295). Loi et al, Wang et al, and Pawitan et al. measured
expression using Affymetrix HG-U133A and HG-U133B arrays.
Van de Vijver et al. measured expression using Agilent cDNA
arrays. Dr. Y. Pawitan kindly provided the ER status of the
samples in Pawitan et al.
Preprocessing of microarray data
For the tumor samples from Pawitan et al., Loi et al., and Wang
et al., we obtained CEL files. The DNA-Chip Analyzer was used
to normalize all CEL files to the baseline arrays and compute the
model-based expression (PM-only model; [20]). For the cell lines
in Neve et al., we obtained already preprocessed data: the
published intensities were in log2 scale and we transformed them
to linear values before computing the dormancy scores.
For the tumor samples from van de Vijver et al. [13], the data
are ratios between the intensity of individual samples and the
average intensity from a cy-labeled cRNA from individual tumor
mixed with the same amount of reverse-color cy-labeled pool that
consisted of an equal amount of cRNA from each patient.
Published ratios of intensities were in log10 scale and we
transformed them to linear values before computing the dormancy
scores.
For multiple Affymetrix probe sets that targeted a common
gene, we used the ‘_at’ probe set with the highest variation
measured by the coefficient of variation. When there were no ‘_at’
probe sets targeting a gene, we retained the ‘_s_at’ probe set with
the highest variation. When neither of those probe set types were
present for a gene, we retained the probe set with the highest
variation.
Computation of dormancy scores
We defined dormancy score for the i












  y yj
where xi1,… ,x i22 are intensities of the 22 up-regulated genes,   x xj is
the average intensity of j
th up-regulated gene across all samples,
yi1,… ,y i27 are intensities of the 27 down-regulated genes, and   y yj is
the average intensity of j
th down-regulated gene across all samples
(Table 1). In van de Vijver et al., the arguments for the logarithmic
functions are directly measured for each gene: the ratio between
the intensity of a sample and the average intensity across all
samples is measured by the relative brightness of cy-labeled cRNA
and reverse-color cy-labeled pool (See Preprocessing of microarray
data). For all other data sets, we computed the ratios by averaging
the intensities across samples. There were no probes for
BHLHE41 or HIST1H2BK in the van de Vijver data set and
thus the calculation of the dormancy score for that data set did not
include those genes, all other data sets included probes for all the
dormancy signature genes.
Statistical Analyses
We performed the Mann-Whitney test [21] to compare
dormancy scores of ER+ versus ER- cell lines or tumors in each
study For analyses pooling samples from all four clinical studies,
Breast Cancer Dormancy Signature
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test, [19]),stratifying by study.
In addition, for each clinical study, we tested the association
between dormancy and the hazard of distant metastasis by first
separating tumors by dormancy score into three equally sized
groups: tumors with High/Mid/Low Dormancy scores, referred
to as HDS, MDS, or LDS, respectively. Then we tested if the
hazards of metastasis were different for the HDS group and LDS
groups by fitting a Cox proportional hazards model [22] using
samples in all three groups. Kaplan-Meier estimates of relapse-free
survival were computed and plotted for 6 groups: ER+ patients
with high dormancy scores (HDS), ER + patients with MDS, ER+
patients with LDS, ER- patients with HDS, ER- patients with
MDS, and ER- patients with LDS. For analysis pooling all samples
from four clinical studies, we performed Cox’s proportional
hazards regression analysis stratified by studies.
We used time-to-distant metastasis in Loi et al. and van de
Vijver et al. as the outcome. In Wang et al. and Pawitan et al., we
used time-to-relapse (local or distant) as outcome because it was
the only available recurrence measurement in their studies. All
statistical analyses were performed using the R statistical
environment [23]. The code and data files used for analysis are
available as supporting information (Text S1, Dataset S1, Dataset
S2, Dataset S3, Dataset S4, Dataset S5 and Dataset S6).
Xenograft studies
The experiments involving animals were performed according
to standards approved by the IACUC of Albert Einstein College of
Medicine and Mount Sinai School of Medicine. For comparing
MCF7, MDA-MB-231 and T47D lines in vivo, lines were grown
in DMEM (Life Technologies) supplemented with 10% FBS
(Atlanta Biologicals) and (Gemini Bio-Products), FBS, and 0.5%
penicillin/streptomycin (Invitrogen). Cells were labeled with 5 uM
CellTrace Violet (Invitrogen) for 20 minutes and then cultured
overnight. The next day, cells were trypsinized, centrifuged to
remove trypsin, resuspended in PBS and diluted 1:1 with Matrigel
to a final concentration of 5 million/ml. 0.1 ml was injected into
the mammary fat pad of 6–8 week old female SCID mice. For
T47D and MCF7 injections, an estrogen pellet (0.36 mg, 60 day
release, Innovative Research of America) was inserted subcutane-
ously the day before injection of tumor cells. Cell Trace labeling
was quantitated using FACS analysis using Rainbow standards.
After 3 days, the animals were euthanized, the mammary fat pad
was dissected out, chopped into fine pieces, and dissociated in PBS
with collagenase IV (final concentration of 6 mg/ml, C5138,
Sigma), hyaluronidase (final concentration of 1 mg/ml, H3506,
Sigma), and DNase I (final concentration of 0.25 mg/ml, D5025-
15KU, Sigma) for 30 minutes with continuous agitation at
37 degrees Celsius. Following digestion, samples were washed
twice in sterile PBS, filtered for single cells, and analyzed by flow
cytometry for level of Cell Trace labeling of tumor cells and
number of tumor cells using the GFP labeling to identify tumor
cells.
For siRNA experiments, MCF-7 cells were cultured on DMEM
medium (Cellgro) supplemented with 10% FBS (HyClone) and 1%
Penicillin/Streptomycin (Gibco). After reaching 80% confluence,
cultures were transfected with siRNAs targeting BHLHE41 (Santa
Cruz), NR2F1 (Ambion) or control scrambled siRNA (Ambion) at
a final concentration of 80 nM using Lipofectamine
TM RNAi-
MAX (Invitrogen) and following the manufacturer instructions. A
second transfection was performed after 24 hours to achieve an
efficient knockdown. siRNA knockdown was analyzed by qPCR
using iQ SYBRH Green Supermix (BioRad). 48 h post-transfec-
tion cells were washed, detached and resuspended on PBS+/+ at a
concentration of 4610
6 cells/70 mL PBS+/+. Prior to injection,
70 mL of Matrigel (Becton Dickinson) was added to the mix and a
total of 140 mL was injected into the left mammary fat pad of
female NSG mice (n=15). Tumors were monitored 3 days after
injection and thereafter for tumor take. Palpable tumors were





RNA was isolated from MCF-7 cells with TRIzolH reagent
following the manufacturer’s indications (Invitrogen). Reverse
transcription was performed using M-MuLV Reverse Transcrip-
tase (New England Biolabs) and quantitative PCR was performed
on a CFX 96
TM Real Time System (BIORAD) using iQ SYBRH
Green Supermix (Invitrogen) using normalization to GAPDH.
The human forward and reverse primer sequences used were:
BHLHE41, 59- CTGATGCTGTTGCTCGGTTA -39 and 59-
TGCAGACTCTGGGACATCTG -39, NR2F1, 59- GCCTCAA-
AGCCATCGTGCTG -39 and 59- CCTCACGTACTCCTC-
CAGTG -39, GAPDH 59-CCCCTGGCCAAGGTCATCCA-39
and 59- ACAGCCTTGGCAGCGCCAGT-39. Statistical analysis
was performed with GraphPad Prism 5.0 (San Diego, CA) and p
values were calculated using one-way ANOVA followed by the
Bonferroni multiple comparison post test or the unpaired t test.
Supporting Information
Text S1 R code that describes the analyses performed with the
supporting information data files.
(PDF)
Data S1 Data set referred to in Text S1 as dt.Loi.signature.xls.
(XLS)
Data S2 Data set referred to in Text S1 as dt.Neve.signature.xls.
(XLS)
Data S3 Data set referred to in Text S1 as dt.NKI295.signa-
ture.xls.
(XLS)
Data S4 Data set referred to in Text S1 as dt.Pawitan.signa-
ture.xls.
(XLS)
Data S5 Data set referred to in Text S1 as dt.Wang.signa-
ture.xls.
(XLS)
Data S6 Data set referred to in Text S1 as si.xls.
(XLS)
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